Related Experiment Videos
Is homozygous alpha-thalassaemia a lethal condition in the 1990s?
1Department of Paediatrics, Prince of Wales Hospital, Chinese University of Hong Kong.
Insights
Homozygous alpha-thalassaemia, once fatal, is now treatable. Active management offers hope but raises ethical and financial concerns, requiring further research before routine use.
Area of Science:
- Medical Genetics
- Hematology
- Neonatology
Background:
- Homozygous alpha-thalassaemia was considered universally fatal, often leading to therapeutic abortion.
- Advances in diagnostics and treatment offer potential cures for this severe genetic blood disorder.
Observation:
- Two cases of homozygous alpha-thalassaemia managed with active treatment are presented.
- One infant survived, while the other, despite respiratory support weaning, died from portal vein thrombosis.
Findings:
- Active management of homozygous alpha-thalassaemia is now feasible.
- This approach presents significant ethical dilemmas and financial burdens on healthcare.
Implications:
- Invasive prenatal and postnatal interventions require further study regarding long-term outcomes and bone-marrow transplant risks.
- Increased access to information may lead to more parental requests for active treatment, necessitating careful consideration of experimental approaches.
Abstract:
Two cases of homozygous alpha-thalassaemia who received active treatment in accordance with parental wishes are reported. One infant survived and the other, although successfully weaned off mechanical respiratory support, unexpectedly developed portal vein thrombosis and died. Homozygous alpha-thalassaemia, a condition previously considered to be universally fatal, and an indication for therapeutic abortion, is now potentially curable with advances in diagnostic technology and treatment. However, active management of these cases raises serious ethical questions and has major financial implications on the health-care system. Invasive prenatal and intensive postnatal interventions should remain experimental and cannot be recommended as routine clinical practice until the questions of long-term neurodevelopmental outcome, and the morbidity and mortality associated with bone-marrow transplantation have been fully addressed. As a result of advances in information technology, more and more parents of affected foetuses are likely to request active treatment.